157P - PCM4EU academy: An educational program for precision oncology

Background

The application of precision oncology needs to educate medical professionals and citizens, including patients and their advocates, researchers, molecular biologists, decision/policymakers, and funding bodies. Increasing the knowledge about new therapies and diagnostics tools, innovative clinical trial design, and innovation in research helps bridge better patient care to clinical practice.

Methods

This project aims to build a comprehensive portfolio of knowledge for various audiences as podcasts and webinars and hybrid courses, including virtual molecular tumor boards. We also explore the different online channels for communication to reach the target population effectively.

Results

Between JAN-JUN 2023, 25 podcasts were recorded (12 in English, 3 in French, 10 in Polish). There are podcasts for medical professionals, and for citizens and patients (either in english or in local languages with subtitles available). Among others are podcasts on molecular screening techniques, the organization of precision medicine in EU, methodologies of personalized oncology clinical trials with information about ongoing DRUP-like trials, cross border access to therapies, pragmatic reimbursement and artificial intelligence in precision oncology. Two interactive training sessions, either in person or hybrid way were realized. Paper reports and recordings are available on the website. Educational materials are available from the project website, as video format on Youtube).

Conclusions

Building an educational pathway by providing high quality educational materials is required to understand the complex and rapidly evolving field of precision oncology. The topics should be popularised also in national languages to reach high range of citizens.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Centre Léon Bérard; Maria Skłodowska-Curie National Research Institute of Oncology.

Funding

This initiative is supported by the Personalized Cancer Medicine for all EU Citizens project (PCM4EU), funded by EU4Health, Europe beating Cancer, Grant 101079984.

Disclosure

L. Verlingue: Financial Interests, Personal, Stocks/Shares, CEO of Resolved dedicated to treatment approval prediction: Resolved; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb; Financial Interests, Institutional, Funding, Contract for bioinformatic analysis: Pierre Fabre, Servier; Non-Financial Interests, Personal, Advisory Role: Klineo; Non-Financial Interests, Institutional, Proprietary Information, As part of the Drug Development Department (DITEP) of Gustave Roussy and of the phase I unit of Centre Léon Bérard, as medical doctor, LV report being: Principal/sub-Investigator of Clinical Trials for AbbVie, Adaptimmune, Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca Ab, Aveo, Basilea Pharmaceutica International Ltd., Bayer Healthcare Ag, BBB Technologies Bv, Beigene, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co, Clovis Oncology, Cullinan-Apollo, Daiichi Sankyo, Debiopharm, Eisai, Eisai Limited, Eli Lilly, Exelixis, Faron Pharmaceuticals Ltd., Forma Therapeutics, GamaMabs, Genentech, GSK, H3 Biomedicine, F.Hoffmann-La Roche Ag, Imcheck Therapeutics, Innate Pharma, Institut De Recherche Pierre Fabre, Iris Servier, Janssen Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin Pharm. Dev, Lilly France, Loxo Oncology, Lytix Biopharma A: Pharmas.J. Blay: Financial Interests, Institutional, Invited Speaker: MSD, MSD, PharmaMar; Financial Interests, Institutional, Advisory Board: Bayer, GSK, Roche; Financial Interests, Personal, Advisory Board: Deciphera; Financial Interests, Personal, Other, member of the supervisory board. No remunerations in 2021 and 2022: Innate pharma; Financial Interests, Personal, Member of Board of Directors: Transgene; Financial Interests, Institutional, Funding: MSD, BMS, Deciphera; Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Bayer, GSK, Novartis, OSE Pharma. I. Lugowska: Financial Interests, Personal, Invited Speaker: Roche, ESMO; Financial Interests, Institutional, Other, Research grants: Roche; Financial Interests, Institutional, Other, Research grant: Agenus; Financial Interests, Personal and Institutional, Invited Speaker: MSD, Roche, BMS, Janssen, Astra, Amgen, RyVu, Incyte, Siropa, Menarini, Celon, Pfizer, Agenus, Rhizen; Non-Financial Interests, Personal, Project Lead: MSCI; Non-Financial Interests, Personal, Other, Board Member: OECI; Other, Personal, Other, Robert Lugowski (my husband) co-ownership: Clininote. All other authors have declared no conflicts of interest.